Helen Mohan

Helen Mohan

Auto-generated profile, based on publicly available information

Helen Mohan

Bowel Cancer Outcomes Registry (BCOR), Melbourne, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HMHelen M. Mohan
Helen M. Mohan
CACarol Aherne
Carol Aherne
ARAilin Rogers
Ailin Rogers
ABAlan W. Baird
Alan W. Baird
DWDes C. Winter
Des C. Winter
EMEvelyn P. Murphy
Evelyn P. Murphy
Nuclear receptors are of integral importance in carcinogenesis. Manipulation of classic ligand-activated nuclear receptors, such as estrogen receptor blockade in breast cancer, is an important established cancer therapy. Orphan nuclear receptors, such as nuclear family 4 subgroup A (NR4A) receptors, have no known natural ligand(s). These elusive receptors are increasingly recognized as molecular switches in cell survival and a molecular link between inflammation and cancer. NR4A receptors act as transcription factors, altering expression of downstream genes in apoptosis (Fas-ligand, TRAIL), proliferation, DNA repair, metabolism, cell migration, inflammation (interleukin-8), and angiogenesis (VEGF). NR4A receptors are modulated by multiple cell-signaling pathways, including protein kinase A/CREB, NF-κB, phosphoinositide 3-kinase/AKT, c-jun-NH2-kinase, Wnt, and mitogen-activated protein kinase pathways. NR4A receptor effects are context and tissue specific, influenced by their levels of expression, posttranslational modification, and interaction with other transcription factors (RXR, PPAR-ϒ). The subcellular location of NR4A “nuclear receptors” is also important functionally; novel roles have been described in the cytoplasm where NR4A proteins act both indirectly and directly on the mitochondria to promote apoptosis via Bcl-2. NR4A receptors are implicated in a wide variety of malignancies, including breast, lung, colon, bladder, and prostate cancer; glioblastoma multiforme; sarcoma; and acute and/or chronic myeloid leukemia. NR4A receptors modulate response to conventional chemotherapy and represent an exciting frontier for chemotherapeutic intervention, as novel agents targeting NR4A receptors have now been developed. This review provides a concise clinical overview of current knowledge of NR4A signaling in cancer and the potential for therapeutic manipulation. Clin Cancer Res; 18(12); 3223–8. ©2012 AACR.

11 May 2013 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
HMH. M. Mohan
H. M. Mohan
MEM. D. Evans
M. D. Evans
JLJ. O. Larkin
J. O. Larkin
JBJ. Beynon
J. Beynon
DWD. C. Winter
D. C. Winter

1 July 2015 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
HMHelen Mohan
Helen Mohan
PNPatrick Nicholson
Patrick Nicholson
DWDes C. Winter
Des C. Winter
DODonal O’shea
Donal O’shea
DODermot O’toole
Dermot O’toole
CCColin P. Cantwell
Colin P. Cantwell

21 February 2020 in Trials
Verified
Journal Article
Open access
PDF file
YLYi Li
Yi Li
HMHelen Mohan
Helen Mohan
NLNan Lan
Nan Lan
XWXiaojian Wu
Xiaojian Wu
WZWei Zhou
Wei Zhou
WZWeiming Zhu
Weiming Zhu
Background: The structures of the mesentery including adipose tissue, nerves, and lymphatics play an important role in the pathogenesis and disease progression of Crohn’s disease (CD). Conventional surgical resection for CD usually does not involve resecting the mesentery en bloc with the specimen. This contrasts with complete mesocolic excision (CME) in colorectal cancer, which involves radical resection of the mesentery. Preliminary evidence from smaller studies suggests that applying the principle of mesocolic excision to CD surgery may reduce the risk of postoperative recurrence. This randomized controlled trial is designed to test whether applying the principles of mesocolic excision to CD results in reduced postoperative recurrence. It also aims to evaluate intra- and postoperative morbidity between the two approaches. Methods: This international, multicenter, randomized controlled trial will randomize patients (n = 116) scheduled to undergo primary ileocolic resection to either receive extensive mesenteric excision (EME) or conventional ileocolic resection with limited mesenteric excision (LME). Five sites will recruit patients in three countries. In the EME group, the mesentery is resected following CME, while avoiding the root region, i.e., 1 cm from the root of the ileocolic artery and vein. In the LME group, the mesentery is retained, i.e., “close shave” or < 3 cm from the border of bowel. The primary end point will be surgical recurrence after surgery. The secondary end points will be the postoperative endoscopic and clinical recurrence, and intra- and postoperative morbidity. Demographics, risk factors, laboratory investigations, endoscopy, postoperative prophylaxis and imaging examination will be assessed. Analysis of the primary outcome will be on an intention-to-treat basis. Discussion: If mesocolic excision in CD reduces postoperative disease recurrence and does not increase morbidity, this trial has the potential to change practice and reduce recurrence of CD after surgical resection. Trial registration: Clinical Trials.gov, ID: NCT03769922. Registered on February 27, 2019.

2 August 2019 in Postgraduate Medical Journal
Verified
Journal Article
Closed access
PDF file
HMHelen Mohan
Helen Mohan
OAOroog Ali
Oroog Ali
VGVimal Gokani
Vimal Gokani
CMCiara McGoldrick
Ciara McGoldrick
PSPeter Smitham
Peter Smitham
RHRhiannon Harries
Rhiannon Harries
Background Internationally, supporting surgical trainees during pregnancy, maternity and paternity leave is essential for trainee well-being and for retention of high-calibre surgeons, regardless of their parental status. This study sought to determine the current experience of surgical trainees regarding pregnancy, maternity and paternity leave. Methods A cross-sectional anonymised electronic voluntary survey of all surgical trainees working in the UK and Ireland was distributed via the Association of Surgeons in Training and the British Orthopaedic Trainees’ Association. Results There were 876 complete responses, of whom 61.4% (n=555) were female. 46.5% (258/555) had been pregnant during surgical training. The majority (51.9%, n=134/258) stopped night on-call shifts by 30 weeks’ gestation. The most common reason for this was concerns related to tiredness and maternal health. 41% did not have rest facilities available on night shifts. 27.1% (n=70/258) of trainees did not feel supported by their department during pregnancy, and 17.1% (n=50/258) found the process of arranging maternity leave difficult or very difficult. 61% (n=118/193) of trainees felt they had returned to their normal level of working within 6 months of returning to work after maternity leave, while a significant minority took longer. 25% (n=33/135) of trainees found arranging paternity leave difficult or very difficult, and the most common source of information regarding paternity leave was other trainees. Conclusion Over a quarter of surgical trainees felt unsupported by their department during pregnancy, while a quarter of male trainees experience difficulty in arranging paternity leave. Efforts must be made to ensure support is available in pregnancy and maternity/paternity leave.

1 June 2013 in Surgical Oncology
Verified
Journal Article
Closed access
HMHelen M. Mohan
Helen M. Mohan
DODonal B. O'COnnor
Donal B. O'COnnor
JOJames M. O'RIordan
James M. O'RIordan
DWDes C. Winter
Des C. Winter